US Stock MarketDetailed Quotes
IPA ImmunoPrecise Antibodies
- 0.403
- +0.003+0.79%
Close Dec 13 16:00 ET
- 0.410
- +0.007+1.67%
Post 20:01 ET
11.63MMarket Cap-0.54P/E (TTM)
0.415High0.400Low156.12KVolume0.400Open0.400Pre Close62.81KTurnover0.62%Turnover RatioLossP/E (Static)28.83MShares2.60052wk High0.51P/B10.22MFloat Cap0.32552wk Low--Dividend TTM25.35MShs Float33.340Historical High--Div YieldTTM3.75%Amplitude0.325Historical Low0.402Avg Price1Lot Size
ImmunoPrecise Antibodies Key Stats
Quarterly+Annual
YOY
| (Q2)Oct 31, 2024 | (Q1)Jul 31, 2024 | (FY)Apr 30, 2024 | (Q4)Apr 30, 2024 | (Q3)Jan 31, 2024 | (Q2)Oct 31, 2023 | (Q1)Jul 31, 2023 | (FY)Apr 30, 2023 | (Q4)Apr 30, 2023 | (Q3)Jan 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -0.41%6.13M | -7.47%5.26M | 18.65%24.52M | 14.91%6.46M | 20.31%6.22M | 18.63%6.15M | 21.31%5.69M | 6.72%20.67M | 7.29%5.62M | 7.39%5.17M |
| Operating revenue | -0.41%6.13M | -7.47%5.26M | 18.65%24.52M | 14.91%6.46M | 20.31%6.22M | 18.63%6.15M | 21.31%5.69M | 6.72%20.67M | 7.29%5.62M | 7.39%5.17M |
| Cost of revenue | -15.89%2.69M | 0.48%2.91M | 36.95%12.47M | 46.97%3.35M | 37.02%3.02M | 32.89%3.2M | 30.90%2.89M | 8.60%9.1M | 18.56%2.28M | -0.99%2.21M |
| Gross profit | 16.35%3.44M | -15.71%2.36M | 4.24%12.05M | -6.97%3.11M | 7.86%3.2M | 6.30%2.95M | 12.75%2.8M | 5.28%11.56M | 0.75%3.34M | 14.62%2.96M |
| Operating expense | 8.63%6.26M | 6.43%6.98M | -30.56%25.82M | -2.33%6.62M | -13.09%6.54M | -45.61%5.76M | -46.58%6.56M | 34.42%37.17M | -10.57%6.78M | 9.70%7.52M |
| Selling and administrative expenses | 6.64%4.51M | -3.35%4.88M | 0.76%19.14M | 9.81%5.03M | -2.45%4.83M | -9.01%4.23M | -3.88%5.05M | 5.18%18.99M | -20.74%4.58M | 14.19%4.95M |
| -Selling and marketing expense | 34.31%1.24M | -32.46%718K | -1.80%3.54M | -2.68%909K | -22.37%649K | 12.73%921K | 4.01%1.06M | 34.73%3.61M | 8.10%934K | 2.96%836K |
| -General and administrative expense | -1.06%3.27M | 4.41%4.16M | 1.36%15.59M | 13.00%4.12M | 1.61%4.18M | -13.65%3.31M | -5.79%3.99M | 0.04%15.38M | -25.81%3.65M | 16.79%4.11M |
| Research and development costs | 38.32%1.16M | 73.39%1.64M | -71.33%4.04M | 1.64%927K | -35.96%1M | -83.31%835K | -84.69%947K | 84.01%14.1M | -31.12%912K | -24.05%1.56M |
| Depreciation amortization depletion | -13.78%613K | -28.45%606K | -32.76%2.97M | -46.77%701K | -31.36%709K | -25.39%711K | -23.83%847K | 119.27%4.41M | 162.35%1.32M | 105.78%1.03M |
| -Depreciation and amortization | -13.78%613K | -28.45%606K | -32.76%2.97M | -46.77%701K | -31.36%709K | -25.39%711K | -23.83%847K | 119.27%4.41M | 162.35%1.32M | 105.78%1.03M |
| Other operating expenses | -37.50%-22K | 48.41%-146K | 0.30%-331K | -23.08%-32K | ---- | -14.29%-16K | -4.81%-283K | -342.67%-332K | -36.84%-26K | 38.89%-22K |
| Operating profit | -0.50%-2.82M | -22.86%-4.63M | 46.27%-13.76M | -2.18%-3.52M | 26.72%-3.34M | 64.08%-2.81M | 61.58%-3.77M | -53.61%-25.61M | 19.38%-3.44M | -6.72%-4.56M |
| Net non-operating interest income expense | -2,500.00%-120K | -125.00%-2K | -95.65%4K | -1,645.45%-340K | -105.13%-2K | -86.11%5K | 260.00%8K | -52.58%92K | -75.28%22K | -71.94%39K |
| Non-operating interest income | ---- | ---- | -81.15%23K | -785.71%-336K | -92.31%3K | -72.22%10K | --8K | -56.27%122K | -55.05%49K | -75.63%39K |
| Non-operating interest expense | 2,300.00%120K | --2K | -36.67%19K | -85.19%4K | --5K | --5K | ---- | -64.71%30K | 35.00%27K | --0 |
| Other net income (expense) | -157.42%-120K | -100.00%-146K | -569.28%-14.95M | -504.20%-14.97M | -51.32%-115K | -29.63%209K | -417.39%-73K | -453.88%-2.23M | -1,203.68%-2.48M | -114.79%-76K |
| Gain on sale of security | -157.42%-120K | -100.00%-146K | -62.11%86K | 482.35%65K | -51.32%-115K | -29.63%209K | -417.39%-73K | -64.03%227K | 91.05%-17K | -114.79%-76K |
| Special income (charges) | ---- | ---- | -511.02%-15.03M | ---- | ---- | ---- | ---- | ---2.46M | ---- | ---- |
| -Less:Impairment of capital assets | ---- | ---- | 511.02%15.03M | ---- | ---- | ---- | ---- | --2.46M | ---- | ---- |
| Income before tax | -18.06%-3.06M | -24.64%-4.78M | -3.43%-28.7M | -219.23%-18.82M | 24.77%-3.46M | 65.35%-2.59M | 60.84%-3.83M | -75.11%-27.75M | -34.95%-5.9M | -27.00%-4.6M |
| Income tax | -178.02%-506K | -86.99%-776K | -28.02%-1.53M | -1.30%-777K | -597.12%-517K | -44.44%-182K | -2.98%-415K | -238.44%-1.19M | -378.91%-767K | -50.00%104K |
| Net income | -5.98%-2.55M | -17.07%-4M | -2.32%-27.18M | -251.82%-18.05M | 37.43%-2.94M | 67.23%-2.41M | 63.59%-3.42M | -58.96%-26.56M | -10.44%-5.13M | -22.82%-4.7M |
| Net income continuous Operations | -5.98%-2.55M | -17.07%-4M | -2.32%-27.18M | -251.82%-18.05M | 37.43%-2.94M | 67.23%-2.41M | 63.59%-3.42M | -58.96%-26.56M | -10.44%-5.13M | -22.82%-4.7M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -5.98%-2.55M | -17.07%-4M | -2.32%-27.18M | -251.82%-18.05M | 37.43%-2.94M | 67.23%-2.41M | 63.59%-3.42M | -58.96%-26.56M | -10.44%-5.13M | -22.82%-4.7M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -5.98%-2.55M | -17.07%-4M | -2.32%-27.18M | -251.82%-18.05M | 37.43%-2.94M | 67.23%-2.41M | 63.59%-3.42M | -58.96%-26.56M | -10.44%-5.13M | -22.82%-4.7M |
| Basic earnings per share | 10.00%-0.09 | -7.14%-0.15 | 0.93%-1.06 | -233.33%-0.7 | 42.11%-0.11 | 66.67%-0.1 | 63.16%-0.14 | -25.88%-1.07 | 8.70%-0.21 | 5.00%-0.19 |
| Diluted earnings per share | 10.00%-0.09 | -7.14%-0.15 | 0.93%-1.06 | -233.33%-0.7 | 42.11%-0.11 | 66.67%-0.1 | 63.16%-0.14 | -25.88%-1.07 | 8.70%-0.21 | 5.00%-0.19 |
| Dividend per share | ||||||||||
| Currency Unit | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD | CAD |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
Heat List
US
Overall
Symbol
Price
% Chg
No Data